Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Therapy with D-TACE, Gem/Cis, and Camrelizumab for Unresectable ICC
NCT05738057Phase 2Recruiting
- Sponsor
- Hua Medicine
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Hua Medicine. Started Jun 2023; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05738057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738057.